Back to Browse Journals » OncoTargets and Therapy » Volume 3

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Authors Steven E McCormack, Erica D Warlick

Published Date July 2010 Volume 2010:3 Pages 157—165

DOI http://dx.doi.org/10.2147/OTT.S5852

Published 22 July 2010

Steven E McCormack, Erica D Warlick

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to ­significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.

Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Shared decision-making in the People’s Republic of China: current status and future directions

Huang RC, Gionfriddo MR, Zhang LZ, Leppin AL, Ting HH, Montori VM

Patient Preference and Adherence 2015, 9:1129-1141

Published Date: 6 August 2015

Impact of noncommunicable diseases in the State of Qatar

Al-Kaabi SK, Atherton A

ClinicoEconomics and Outcomes Research 2015, 7:377-385

Published Date: 2 July 2015

Oxidative stress and antibacterial properties of a graphene oxide-cystamine nanohybrid

Nanda SS, An SS, Yi DK

International Journal of Nanomedicine 2015, 10:549-556

Published Date: 12 January 2015

Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals

Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2014, 9:1139-1152

Published Date: 3 March 2014

A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery

Li P, Liu DH, Miao L, Liu CX, Sun XL, Liu YJ, Zhang N

International Journal of Nanomedicine 2012, 7:925-939

Published Date: 21 February 2012

Update on current and emerging treatment options for post-polio syndrome

Elisabeth Farbu

Therapeutics and Clinical Risk Management 2010, 6:307-313

Published Date: 7 July 2010